Literature DB >> 15023471

Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice.

Moses O Oyewumi1, Robert A Yokel, Michael Jay, Tricia Coakley, Russell J Mumper.   

Abstract

The purpose of these studies was to compare the cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium (Gd) nanoparticles. Gd is a potential agent for neutron capture therapy (NCT) of tumors. Gd nanoparticles were engineered from oil-in-water microemulsion templates. To obtain folate-coated nanoparticles, a folate ligand [folic acid chemically linked to distearoylphosphatidylethanolamine (DSPE) via a PEG spacer MW 3350] was included in nanoparticle preparations. Similarly, control nanoparticles were coated with DSPE-PEG-MW 3350 (PEG-coated). Nanoparticles were characterized based on size, size distribution, morphology, biocompatibility and tumor cell uptake. In vivo studies were carried out in KB (human nasopharyngeal carcinoma) tumor-bearing athymic mice. Biodistribution and tumor retention studies were carried out at pre-determined time intervals after injection of nanoparticles (10 mg/kg). Gd nanoparticles did not aggregate platelets or activate neutrophils. The retention of nanoparticles in the blood 8, 16 and 24 h post-injection was 60%, 13% and 11% of the injected dose (ID), respectively. A maximum Gd tumor localization of 33+/-7 microg Gd/g was achieved. Both folate-coated and PEG-coated nanoparticles had comparable tumor accumulation. However, the cell uptake and tumor retention of folate-coated nanoparticles was significantly enhanced over PEG-coated nanoparticles. Thus, the benefits of folate ligand coating were to facilitate tumor cell internalization and retention of Gd-nanoparticles in the tumor tissue. The engineered nanoparticles may have potential in tumor-targeted delivery of Gd thereby enhancing the therapeutic success of NCT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023471     DOI: 10.1016/j.jconrel.2004.01.002

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  48 in total

1.  A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo.

Authors:  Suna He; Zheng Cui; Dong Mei; Hua Zhang; Xueqing Wang; Wenbing Dai; Qiang Zhang
Journal:  AAPS PharmSciTech       Date:  2012-05-30       Impact factor: 3.246

2.  Ligand-decorated click polypeptide derived nanoparticles for targeted drug delivery applications.

Authors:  Mohiuddin A Quadir; Stephen W Morton; Lawrence B Mensah; Kevin Shopsowitz; Jeroen Dobbelaar; Nicole Effenberger; Paula T Hammond
Journal:  Nanomedicine       Date:  2017-03-02       Impact factor: 5.307

Review 3.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Nanotechnology of emerging targeting systems.

Authors:  S S Smith
Journal:  Minerva Biotecnol       Date:  2008-09       Impact factor: 3.028

5.  Multifunctional yolk-in-shell nanoparticles for pH-triggered drug release and imaging.

Authors:  Hongyu Chen; Bin Qi; Thomas Moore; Fenglin Wang; Daniel C Colvin; Liurukara D Sanjeewa; John C Gore; Shiou-Jyh Hwu; O Thompson Mefford; Frank Alexis; Jeffrey N Anker
Journal:  Small       Date:  2014-04-19       Impact factor: 13.281

6.  Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding.

Authors:  Xiue Jiang; Stefan Weise; Margit Hafner; Carlheinz Röcker; Feng Zhang; Wolfgang J Parak; G Ulrich Nienhaus
Journal:  J R Soc Interface       Date:  2009-09-23       Impact factor: 4.118

7.  Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images.

Authors:  Tatjana Paunesku; Tianyi Ke; Rohan Dharmakumar; Nicole Mascheri; Aiguo Wu; Barry Lai; Stefan Vogt; Jörg Maser; Kenneth Thurn; Barbara Szolc-Kowalska; Andrew Larson; Raymond C Bergan; Reed Omary; Debiao Li; Zheng-Rong Lu; Gayle E Woloschak
Journal:  Nanomedicine       Date:  2008-06-24       Impact factor: 5.307

8.  Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

Authors:  Ping Ma; Xiaowei Dong; Courtney L Swadley; Anshul Gupte; Markos Leggas; Harry C Ledebur; Russell J Mumper
Journal:  J Biomed Nanotechnol       Date:  2009-04       Impact factor: 4.099

9.  Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation.

Authors:  Björn Gustafsson; Susan Youens; Angelique Y Louie
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

Review 10.  Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.

Authors:  Melike Uner; Gülgün Yener
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.